Acceleron Pharma Inc. (XLRN)

46.30
0.20 0.43
NASDAQ : Health Technology
Prev Close 46.50
Open 46.18
Day Low/High 44.87 / 46.41
52 Wk Low/High 29.57 / 50.00
Volume 383.35K
Avg Volume 435.30K
Exchange NASDAQ
Shares Outstanding 45.77M
Market Cap 2.12B
EPS -2.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Robert K. Zeldin, M.D., Named Chief Medical Officer, Acceleron Pharma Inc.

Robert K. Zeldin, M.D., Named Chief Medical Officer, Acceleron Pharma Inc.

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the appointment of Robert K.

Celgene And Acceleron Announce Luspatercept Achieved Primary And Key Secondary Endpoints In Phase III 'MEDALIST' Study In Patients With Low-to-Intermediate Risk Myelodysplastic Syndromes

Celgene And Acceleron Announce Luspatercept Achieved Primary And Key Secondary Endpoints In Phase III 'MEDALIST' Study In Patients With Low-to-Intermediate Risk Myelodysplastic Syndromes

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (MEDALIST).

Acceleron To Present Preliminary Data On ACE-083 At The 2018 Annual Meeting Of The Peripheral Nerve Society

Acceleron To Present Preliminary Data On ACE-083 At The 2018 Annual Meeting Of The Peripheral Nerve Society

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver oral and poster presentations on ACE-083 from the...

Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Beta-Thalassemia At The 23rd Congress Of The European Hematology Association

Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Beta-Thalassemia At The 23rd Congress Of The European Hematology Association

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced updated results from the ongoing Phase 2 trials of luspatercept in...

Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Myelodysplastic Syndromes At The ASCO 2018 Annual Meeting

Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Myelodysplastic Syndromes At The ASCO 2018 Annual Meeting

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced updated results from the Phase 2 trials of luspatercept in patients with...

Acceleron Announces Initiation Of PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension

Acceleron Announces Initiation Of PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the initiation of the PULSAR Phase 2 trial of sotatercept for the...

Acceleron Announces Presentations On Luspatercept At The 23rd Congress Of The European Hematology Association

Acceleron Announces Presentations On Luspatercept At The 23rd Congress Of The European Hematology Association

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three presentations on luspatercept at the 23 rd...

Noteworthy Friday Option Activity: XLRN, VRAY, AKRX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acceleron Pharma, Inc. , where a total of 2,988 contracts have traded so far, representing approximately 298,800 underlying shares.

Acceleron Reports First Quarter 2018 Operating And Financial Results

Acceleron Reports First Quarter 2018 Operating And Financial Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the first quarter...

Acceleron To Participate In Two Healthcare Investor Conferences In May

Acceleron To Participate In Two Healthcare Investor Conferences In May

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare...

Acceleron Receives FDA Fast Track Designation For ACE-083 In Facioscapulohumeral Muscular Dystrophy (FSHD)

Acceleron Receives FDA Fast Track Designation For ACE-083 In Facioscapulohumeral Muscular Dystrophy (FSHD)

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the U.

Acceleron To Webcast First Quarter 2018 Operating And Financial Results On May 8, 2018

Acceleron To Webcast First Quarter 2018 Operating And Financial Results On May 8, 2018

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, May 8, 2018 at 5:00 p.

Acceleron Announces ACE-083 Phase 2 Trial Presentation At The American Academy Of Neurology 70th Annual Meeting

Acceleron Announces ACE-083 Phase 2 Trial Presentation At The American Academy Of Neurology 70th Annual Meeting

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that preliminary results from the ongoing Phase 2 trial of ACE-083 in...

Acceleron Announces Presentations On Lead Product Candidate Luspatercept At The 2018 American Society Of Clinical Oncology Annual Meeting

Acceleron Announces Presentations On Lead Product Candidate Luspatercept At The 2018 American Society Of Clinical Oncology Annual Meeting

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that two abstracts on lead product candidate luspatercept will be...

Acceleron To Host Educational Webinar With Leading Clinicians To Provide An Overview Of Pulmonary Arterial Hypertension (PAH) And The Sotatercept Phase 2 Trial

Acceleron To Host Educational Webinar With Leading Clinicians To Provide An Overview Of Pulmonary Arterial Hypertension (PAH) And The Sotatercept Phase 2 Trial

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that it will host an educational webinar...

Acceleron Announces Publication Of ACE-083 Phase 1 Trial Results In Muscle & Nerve

Acceleron Announces Publication Of ACE-083 Phase 1 Trial Results In Muscle & Nerve

Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the journal Muscle & Nerve...

Acceleron Reports Fourth Quarter And Full Year 2017 Operating And Financial Results

Acceleron Reports Fourth Quarter And Full Year 2017 Operating And Financial Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial...

Acceleron To Webcast Fourth Quarter And Full Year 2017 Operating And Financial Results On February 27, 2018

Acceleron To Webcast Fourth Quarter And Full Year 2017 Operating And Financial Results On February 27, 2018

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, February 27, 2018 at 5:00 p.

Sujay Kango Named Chief Commercial Officer, Acceleron Pharma Inc.

Sujay Kango Named Chief Commercial Officer, Acceleron Pharma Inc.

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the appointment of commercial industry...

Acceleron To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Acceleron To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that members of the management team...

Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy

Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced positive preliminary results for the...

Acceleron Announces Planned Retirement Of Chief Medical Officer, Dr. Matthew L. Sherman

Acceleron Announces Planned Retirement Of Chief Medical Officer, Dr. Matthew L. Sherman

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the planned retirement of Executive Vice...

Acceleron To Webcast Presentation At The 36th Annual J.P. Morgan Healthcare Conference

Acceleron To Webcast Presentation At The 36th Annual J.P. Morgan Healthcare Conference

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that Habib Dable, President and...

Interesting XLRN Put And Call Options For August 2018

Interesting XLRN Put And Call Options For August 2018

Investors in Acceleron Pharma, Inc. saw new options begin trading this week, for the August 2018 expiration.

Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Myelodysplastic Syndromes At The 59th Annual Meeting Of The American Society Of Hematology

Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Myelodysplastic Syndromes At The 59th Annual Meeting Of The American Society Of Hematology

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced preliminary results from the ongoing...

Acceleron To Host Conference Call And Webcast To Review Data Presented At The 59th American Society Of Hematology Annual Meeting And Exposition

Acceleron To Host Conference Call And Webcast To Review Data Presented At The 59th American Society Of Hematology Annual Meeting And Exposition

Acceleron Pharma Inc. (NASDAQ:XLRN) will host a conference call and live audio webcast on Monday, December 11, 2017 at 7:00 a.

Acceleron Announces Appointment Of Dr. Karen Smith To Its Board Of Directors And Departure Of Terrance McGuire

Acceleron Announces Appointment Of Dr. Karen Smith To Its Board Of Directors And Departure Of Terrance McGuire

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced the appointment of the experienced biopharmaceutical executive, Karen Smith, M.

Acceleron Announces Preclinical Results In Pulmonary Arterial Hypertension At The American Heart Association 2017 Scientific Sessions

Acceleron Announces Preclinical Results In Pulmonary Arterial Hypertension At The American Heart Association 2017 Scientific Sessions

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced new preclinical results with sotatercept...

TheStreet Quant Rating: D (Sell)